REGN — REGENERON PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 872589 ·
Last close
$957.76
Market Cap
$97.34B
52W High
$991.73
52W Low
$590.83
ADV30
899,500
Next earnings
2027-01-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 5,115,800,000 | 4,542,200,000 | 2,069,700,000 | 1,948,700,000 | 44,405,200,000 | 3,659,100,000 | 10,906,700,000 |
| Jun 2026 | 4,290,700,000 | 3,714,200,000 | 1,420,500,000 | 1,296,900,000 | 41,730,600,000 | 2,455,800,000 | 10,019,200,000 |
| Mar 2026 | 3,605,400,000 | 2,936,000,000 | 744,800,000 | 727,200,000 | 40,868,800,000 | 2,962,600,000 | 9,445,200,000 |
| Dec 2025 | 3,884,300,000 | 3,299,700,000 | 898,600,000 | 844,600,000 | 40,558,700,000 | 3,118,100,000 | 9,301,800,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,681,300,000
Investing CF
$-704,200,000
Financing CF
$-3,524,800,000
CapEx
$-1,106,100,000
Dividends Paid
$-378,500,000
Buybacks
$-3,902,400,000
EPS Diluted TTM
$40.46
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$37,621,400,000
Inventory
$3,084,300,000
Receivables
$6,565,400,000
ST Investments
$5,538,800,000
EBIT TTM
$5,221,400,000
Pretax Income TTM
$5,166,000,000
Interest Exp TTM
$55,400,000
Analysts
27
Yahoo Snapshot (yfinance, live)
Total Revenue
$16,896,199,680
EBITDA
$5,649,699,840
Free Cash Flow
$3,065,299,968
Enterprise Value
$78,214,914,048
Total Cash
$18,858,500,096
Total Debt
$2,707,000,064
Shares Out
101,630,713
Trailing EPS
$45.24
Book Value
$329.39
ROE
14.9%
ROA
7.6%
Div Yield
0.41%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,342,900,000 | 3,702,000,000 | 4,504,900,000 | 40,558,700,000 | 9,301,800,000 | 31,256,900,000 | 4,978,900,000 |
| Dec 2024 | 14,202,000,000 | 3,990,700,000 | 4,412,600,000 | 37,759,400,000 | 8,405,800,000 | 29,353,600,000 | 4,420,500,000 |
| Dec 2023 | 13,117,200,000 | 4,047,100,000 | 3,953,600,000 | 33,080,200,000 | 7,107,100,000 | 25,973,100,000 | 4,594,000,000 |
| Dec 2022 | 12,172,900,000 | 4,738,900,000 | 4,338,400,000 | 29,214,500,000 | 6,550,500,000 | 22,664,000,000 | 5,014,900,000 |
TTM Snapshot
Revenues TTM
$15,534,700,000
NetIncome TTM
$4,328,700,000
OpCashFlow TTM
—
Assets (Latest)
$41,730,600,000
Forward EPS
$66.94
Max Pain — expiry 2026-12-18
max pain strike: $735.00 · spot: $945.53 · call oi: 439 · put oi: 691
Expected Move to 2026-12-18:
±$80.60
(8.52%) —
implied range
$864.93 –
$1026.13
· ATM straddle on $945.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GSK | GSK plc | $98.62B | $49.24 | — |
| SNY | Sanofi | $113.89B | $47.53 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $125.40B | $61.35 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $135.44B | $534.20 | — |
| NVO | NOVO NORDISK A S | $136.10B | $40.70 | — |
News headlines (Yahoo Finance, 1h cache)
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
2026-11-18 23:03 · Yahoo
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
2026-11-18 18:10 · Yahoo
Should You Pick Vertex Stock Over Its Biotech Rivals?
2026-11-18 17:13 · Yahoo
Does Flexible Libtayo Dosing Change The Bull Case For Regeneron Pharmaceuticals Stock?
2026-11-18 07:08 · Yahoo
Regeneron Pharmaceuticals (REGN), Why Is The Market Taking A Closer Look?
2026-11-18 06:15 · Yahoo
Regeneron (REGN) Stock Trades Below Fair Value As POTS Trial Progresses
2026-11-18 05:10 · Yahoo
CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
2026-11-17 21:15 · Yahoo
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval
2026-11-17 18:13 · Yahoo
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
2026-11-17 15:00 · Yahoo
Can Regeneron Stock Hit $1,400?
2026-11-17 14:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.